Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on SalesTimes Interest Earned

Gsk (GLAXF) Enterprise Value (2016 - 2025)

Historic Enterprise Value for Gsk (GLAXF) over the last 17 years, with Q3 2025 value amounting to -$4.8 billion.

  • Gsk's Enterprise Value rose 681.96% to -$4.8 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.8 billion, marking a year-over-year increase of 681.96%. This contributed to the annual value of -$5.4 billion for FY2024, which is 2303.09% up from last year.
  • Gsk's Enterprise Value amounted to -$4.8 billion in Q3 2025, which was up 681.96% from -$5.7 billion recorded in Q2 2025.
  • In the past 5 years, Gsk's Enterprise Value ranged from a high of $3.7 billion in Q3 2021 and a low of -$9.7 billion during Q4 2022
  • For the 5-year period, Gsk's Enterprise Value averaged around -$3.5 billion, with its median value being -$4.8 billion (2023).
  • As far as peak fluctuations go, Gsk's Enterprise Value skyrocketed by 102153.1% in 2021, and later tumbled by 115387.52% in 2023.
  • Quarter analysis of 5 years shows Gsk's Enterprise Value stood at $2.7 billion in 2021, then crashed by 459.29% to -$9.7 billion in 2022, then rose by 27.54% to -$7.1 billion in 2023, then increased by 22.55% to -$5.5 billion in 2024, then increased by 11.76% to -$4.8 billion in 2025.
  • Its Enterprise Value stands at -$4.8 billion for Q3 2025, versus -$5.7 billion for Q2 2025 and -$6.4 billion for Q1 2025.